OverviewChartNewsTraderScreen

BAVARIAN NORDIC A/S/  DK0015998017  /

Turquoise
2024-05-14  5:18:53 PM Chg. +5.75 Volume Bid- Ask- High Low
171.65DKK +3.47% 6,746
Turnover: 1.13 mill.		 -Bid Size: - -Ask Size: - 171.65 165.50
GlobeNewswire 05-07 Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
GlobeNewswire 04-29 Bavarian Nordic Initiates Rolling Submission of Biologics License Application with FDA for its Chiku...
GlobeNewswire 04-02 Bavarian Nordic Announces Commercial Launch of Mpox Vaccine in the U.S.
GlobeNewswire 03-20 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
GlobeNewswire 02-23 Bavarian Nordic’s Chikungunya Vaccine Candidate Granted Accelerated Assessment by European Medicines...
GlobeNewswire 02-15 Valneva Reports Full Year 2023 Revenue and Cash, Provides First 2024 Guidance
GlobeNewswire 2023-11-09 Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates
GlobeNewswire 2023-11-08 Emergent BioSolutions Reports Third Quarter 2023 Financial Results
GlobeNewswire 2023-09-21 Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates
TeleTrader 2022-08-19 EU makes monkeypox vaccine more available
TeleTrader 2022-08-18 WH announces new strategies against monkeypox
TeleTrader 2022-07-30 Spain confirms second monkeypox death
TeleTrader 2022-07-29 Spain confirms Europe's first monkeypox death
TeleTrader 2022-07-25 Monkeypox vaccine approved by EU
TeleTrader 2022-07-22 EMA gives preliminary approval to monkeypox jab
TeleTrader 2022-06-14 EU buys 110,000 monkeypox vaccines
TeleTrader 2022-05-27 EU to jointly buy antivirals, vaccines against monkeypox
GlobeNewswire 2022-03-24 Valneva Reports Full Year 2021 Results and Provides Corporate Updates
GlobeNewswire 2022-03-21 Bavarian Nordic Announces License and Supply Agreement with Nuance Pharma on the Development and Com...
GlobeNewswire 2022-02-28 Bavarian Nordic Reports Additional Positive Phase 2 Results for its COVID-19 Vaccine Candidate Ahead...
GlobeNewswire 2022-02-14 Bavarian Nordic Announces Breakthrough Therapy Designation for its RSV Vaccine Candidate for the Pre...
GlobeNewswire 2022-02-03 Valneva Reports Full Year 2021 Revenue and Cash; Provides First 2022 Guidance
GlobeNewswire 2021-12-06 Bavarian Nordic Commits to Initiating Phase 3 Trial of RSV Vaccine Candidate and to Strengthening it...
GlobeNewswire 2021-12-05 Bavarian Nordic Reports Positive Topline Phase 2 Results for its COVID-19 Vaccine Candidate
GlobeNewswire 2021-11-18 Valneva Reports Nine-Month 2021 Revenue and Cash